Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV

Inclusion Criteria Patients must have: * Positive AFB smear and/or culture for Mycobacterium tuberculosis, M. avium, or other mycobacterial infection, with or without documented HIV infection. NOTE: * HIV-positive patients must have CD4 count \< 500 cells/mm3 and be on antiretroviral therapy. * One of the following manifestations: * Temperature over 38 C on at least two occasions in the week prior to study entry. * Recent weight loss of more than 5 kilograms. * Pulmonary involvement of one or more lobes or involvement of other tissues due to tuberculosis or other mycobacterial infections, or symptomatic infections related to HIV status. * Night sweats on two or more occasions in the week prior to study entry. NOTE: * Patients must be hospitalized men aged 18-65 and postmenopausal women to age 65. Anticipated requirement for hospitalization must be at least 10 days. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Neuropathy or other disorders with risk of neuropathy. Required for HIV-positive patients if CD4 count \< 500 cells/mm3: * Antiretroviral therapy.